Assessment of Sleep Disturbance in Alzheimer Disease - Full Text View

Sponsor:	Centre Hospitalier Universitaire de Nice
Information provided by (Responsible Party):	Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:	NCT00831298

Purpose

The purpose of this study is to study circadian rhythms, or daily cycles of sleep, wake, and activity. The investigators hope to learn how disturbed sleep in Alzheimer's Disease relates to changes in activity cycles, and how sleep disturbances may affect your daytime alertness.

This project selects patients suffering from memory problems, or voluntary to be in our Control Group. There are three parts to this study: Sleep Diaries, Behavioral Questionnaire, and Activity Recordings

Condition	Intervention
Alzheimer Disease	Other: Analysis of sleep disturbance

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science
Official Title:	Assessment of Sleep Disturbance in Alzheimer Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease Memory Sleep Disorders

U.S. FDA Resources

Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:

assessment of apathy [ Time Frame: at day 0, just after inclusion ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

assessment of sleep disturbance [ Time Frame: during a week, between day 0 and day 7 ] [ Designated as safety issue: No ]
determine a genetic relationship between sleep disturbance and alzheimer disease [ Time Frame: after all genetic analyses of the study ] [ Designated as safety issue: No ]

Enrollment:	70
Study Start Date:	July 2010
Study Completion Date:	November 2011
Primary Completion Date:	November 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1 Behavioral Questionnaire Sleep Recordings Genetic analysis	Other: Analysis of sleep disturbance Behavioral Questionnaire Sleep Recordings Genetic analysis

Eligibility

Ages Eligible for Study:	65 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

alzheimer disease
MMSE > 20
over 65 years old

Exclusion Criteria:

new psychotropic drug treatment
patient unable to do neuropsychologic tests

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00831298

Locations

France
Centre Mémoire de Ressources et de Recherche, CHU de Nice
Nice, France, 06000

Sponsors and Collaborators

Centre Hospitalier Universitaire de Nice

Investigators

Principal Investigator:

Philippe ROBERT

Centre Hospitalier Universitaire de Nice

More Information

No publications provided

Responsible Party:	Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:	NCT00831298 History of Changes
Other Study ID Numbers:	08-PP-07
Study First Received:	January 27, 2009
Last Updated:	December 8, 2011
Health Authority:	France: Afssaps - French Health Products Safety Agency; France: French Data Protection Authority; France: Institutional Ethical Committee

Keywords provided by Centre Hospitalier Universitaire de Nice:

alzheimer disease
sleep disturbance
apathy
memory loss

Additional relevant MeSH terms:

Alzheimer Disease
Sleep Disorders
Dyssomnias
Parasomnias
Dementia
Brain Diseases
Central Nervous System Diseases

Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on February 09, 2012